2000  Update of Recommendations for the Use of  Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice  Guidelines

Smith, Thomas J.; Ozer, Howard; Miller, Langdon L.; Schiffer, Charles A.; Winn, Rodger J.; Anderson, James R.; Anderson, Paul N.; Armitage, Jamés O.; Beckhardt, Stacey; Bennett, Charles L.; Bodey, Gerald P.; Crawford, Jeffrey; Davidson, Nancy E.; Demetri, George D.; Hamm, John; Hillner, Bruce E.; Kardinal, Carl G.; Levine, Mark; Miller, John A.; Ochs, Judith J.; Santana, Víctor M.; Shea, Thomas C.; Vadhan‐Raj, Saroj; Wade, James L.; Weeks, Jane C.

doi:10.1200/jco.2000.18.20.3558

Cited by 747 publications

(387 citation statements)

References 135 publications

Supporting

Mentioning

355

Contrasting

Unclassified

Order By: Relevance

“…25 In the present study, we observed that recipients of autologous PBPC transplants who received G-CSF starting on day +1 had a slightly shorter median duration of neutropenia when compared to patients who started G-CSF on day +5. However, after stratified analysis, the beneficial effect was evident only in patients who had been conditioned with melphalan, and received more than 3.0 ϫ 10 6 CD34 + cells/kg.…”

Section: Discussionsupporting

confidence: 55%

A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation

Azevedo

Nucci

Maiolino

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:In order to assess the effect of delaying G-CSF administration after autologous peripheral blood progenitor cell (PBPC) transplantation on the duration of neutropenia, 87 patients were randomized to receive G-CSF 5 g/kg/day starting on day +1 (n = 45) or +5 (n = 42) following PBPC transplantation, until recovery of the neutrophils. The duration of neutropenia (Ͻ0.5 ؋ 10 9 /l) was shorter in the day +1 group (7 vs 8 days; P = 0.02), especially in patients receiving melphalan 200 mg/m 2 and CD34 + cell doses Ͼ3.0 ؋ 10 6 /kg. These patients had a later onset of neutropenia after transplant. There were no differences in time to neutrophil and platelet engraftment, or in the incidence of fever and documentation of infection. Although the duration of antibiotic therapy (7 vs 10.5 days; P = 0.01) and time to hospital discharge (13 vs 15 days; P = 0.02) were shorter in the day +1 group, these differences could not be predicted by the day of G-CSF initiation in multivariate analysis. Starting G-CSF on day +1 does not result in faster neutrophil engraftment but in later onset and consequently, slightly shorter duration of neutropenia in patients who receive melphalan 200 mg/m 2 and CD34 + cell doses Ͼ3.0 ؋ 10 6 /kg. Bone Marrow Transplantation (2002) 29, 745-751.

show abstract

Section: Discussionsupporting

confidence: 55%

A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation

Azevedo

Nucci

Maiolino

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Based on these findings, the American Society of Clinical Oncology and the Haemato-Oncology Task Force of the British Committee for Standards in Haematology recommend the use of G-CSF after high-dose therapy and autologous PBPCT. 13,14 With respect to important clinical end points such as the incidence of infections, the use of i.v. antibiotics, the number of days spent in hospital, red blood cell, and platelet transfusion requirements, and the need for parenteral nutrition, the randomized studies have shown equivocal results and most have been negative, that is, they were unable to demonstrate a clinical benefit of growth factor administration after transplantation of hematopoietic stem cells.…”

Section: Discussionmentioning

confidence: 99%

“…After reinfusion of the harvest products, the median time to neutrophil recovery was 11 days (95% confidence interval (CI) 10-11 days) in the patients treated with lenograstim and 15 days (95% CI 14-16) in patients treated with placebo after transplantation (Po0.001). The median time to platelet independence was 15 days (95% CI [13][14][15][16] in the lenograstim and 13 days (95 % CI 12-13) in the placebo group (P ¼ 0.33). There were no significant differences in the numbers of RBC or platelet transfusions given after PBPCT.…”

Section: Hematopoietic Recoverymentioning

confidence: 99%

Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial

Schmitz

Ljungman

Cordonnier³

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Growth factor support usage was according to the American Society of Clinical Oncology guidelines, and growth factor support was not used to maintain dose intensity. 12 Prior to study entry, all patients underwent physical examination and had their ECOG performance status and weight documented. There also was a pretherapy complete blood count (CBC) and differential, serum creatinine, blood urea nitrogen, AST, bilirubin, and computed tomography (CT) scans of the chest and or abdomen.…”

Section: Methodsmentioning

confidence: 99%

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium

Dreicer

Manola

Schneider

et al. 2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDGemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemotherapy regimen.METHODSTwenty‐nine eligible patients with advanced urothelial carcinoma were treated with docetaxel at a dose of 40 mg/m2 over 1 hour followed by gemcitabine, 800 mg/m2, over 30 minutes, both intravenously (i.v.) on Days 1 and 8. Cycles were repeated every 21 days until disease progression or a maximum of 6 cycles.RESULTSFive patients obtained an objective response for an overall response rate of 17% (90% confidence interval, 7–33%). One patient achieved a complete clinical response. The median overall survival of the group was 7.7 months. Toxicity was moderate with granulocytopenia, anorexia, and fatigue being the most commonly noted side effects.CONCLUSIONSGemcitabine and docetaxel is an active second‐line combination in patients with advanced urothelial carcinoma. Responses in visceral, lymph node, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and anorexia was common. Thromboembolic symptoms were reported and are of concern. The combination of gemcitabine and docetaxel has the potential to palliate a subset of previously treated patients with an adequate performance status. Cancer 2003;97:2743–7. © 2003 American Cancer Society.DOI 10.1002/cncr.11413

show abstract

2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines

Cited by 747 publications

References 135 publications

A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation

A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation

Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium

Contact Info

Product

Resources

About